Actively Recruiting

Phase Not Applicable
Age: 18Years - 50Years
All Genders
NCT03811236

Cold-induced Brown Fat Activation and Hepatic Steatosis

Led by Medical University of Vienna · Updated on 2024-03-13

26

Participants Needed

1

Research Sites

410 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In the recent years, research on brown adipose tissue (BAT) revealed that larger amounts as well as higher activity thereof are associated with a favourable metabolic phenotype. Longitudinal studies which applied recurrent cooling sessions demonstrated a high plasticity of BAT which significantly increased in size and activity during these studies. These changes were accompanied by improvements in body fat mass as well as insulin sensitivity. Non-alcoholic fatty liver disease (NAFLD) is estimated to advance to the primary cause of liver cirrhosis and hepatocellular carcinoma in the following years. Besides predisposing genetic and possibly nutritional factors, the insulin resistance syndrome and obesity are the main factors contributing to this excessive hepatic lipid accumulation. The aim of this study is to investigate whether BAT recruitment via cold-acclimation results in decreased hepatic lipid content in overweight/obese patients with NAFLD.

CONDITIONS

Official Title

Cold-induced Brown Fat Activation and Hepatic Steatosis

Who Can Participate

Age: 18Years - 50Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Body mass index 28 - 40 kg/m²
  • Hepatic lipid content greater than 10%
Not Eligible

You will not qualify if you...

  • Endocrine disease except treated hypo-/hyperthyroidism and certain hypertriglyceridemia (less than 500 mg/dl) and untreated type II diabetes mellitus with fasting glucose below 140 mg/dl
  • Use of beta-blockers, alpha-blockers, and rilmenidine
  • Chronic kidney disease
  • Inflammatory bowel disease
  • Active malignant disease
  • Autoimmune disease
  • Chronic alcohol abuse or alcohol consumption over 30g per day for men or 20g per day for women
  • Transferrin saturation greater than 40%
  • Serum alpha-1 antitrypsin below 90 mg/dl
  • Serum ceruloplasmin below 20 mg/dl
  • Positive serology for autoimmune hepatitis
  • Positive hepatitis serology
  • Liver cirrhosis
  • Portal hypertension
  • Pregnancy
  • Contraindications for magnetic resonance imaging

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Medical University of Vienna

Vienna, Austria, 1090

Actively Recruiting

Loading map...

Research Team

F

Florian Kiefer, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here